ALF Centurion Acquisition Corporation

On July 1, 2022, Allen Capsuto, a member of the Board of Directors (the “Board”) of Alfi, Inc. (the “Company”) and Chairman of the Audit Committee of the Board (the “Audit Committee”), notified the Company that he is resigning his position as a director of the Company and as Audit Committee Chair, effective July 14, 2022. Mr. Capsuto’s resignation is not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On July 7, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jeremy D. Daniel to serve as a director of the Company to fill the vacancy on the Board created by Mr. Capsuto’s resignation, effective July 14, 2022 and immediately upon the effectiveness of such resignation (the “Effective Time”). The Board also appointed Mr. Daniel as a member of the Audit Committee and as Audit Committee Chair, in each case effective as of the Effective Time.

Mr. Daniel, age 46, has served since 2019 as the Chief Financial Officer of H-CYTE, Inc. (“H-CYTE”), a public reporting hybrid biopharmaceutical company dedicated to developing and delivering a novel portfolio of new diagnostics, therapeutics, and medical devices from concept to commercialization. From 2013 to 2019, Mr. Daniel served as Chief Financial Officer of Regenerative Medicine Solutions, LLC, which was acquired by H-CYTE in 2019. He currently serves on the Board of Directors of Medovex LLC, a subsidiary of H-CYTE. Mr. Daniel received his BS in Accounting from the University of Cincinnati and his MBA from Xavier University.

In connection with his appointment to the Board, the Board determined that Mr. Daniel is independent under the independence standards of the Nasdaq Stock Market (“Nasdaq”) and is independent under the rules of Nasdaq and the Securities and Exchange Commission (the “SEC”) for purposes of service on the Audit Committee. There are no arrangements or understandings between Mr. Daniel and any other person pursuant to which he was selected as a director, and there are no relationships or transactions in which Mr. Daniel has an interest requiring disclosure under Item 404(a) of Regulation S-K. Mr. Daniel will participate in the Company’s director compensation program, which is described under the heading “Director Compensation” in Item 11., Executive Compensation, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on May 16, 2022.